ophthalmologytimes1d
HuidaGene Therapeutics' IND application for HG202 for the treatment of nAMD cleared by FDA
FDA clearance of HG202 marks a significant milestone for CRISPR/Cas13 RNA-editing in clinical applications for nAMD. The ...
ophthalmologytimes10h
Harrow announces expanded market access for cyclosporine ophthalmic solution in 2025 Medicare Part D Program
Vevye will be included in key formularies of major plan sponsors, covering over 25 million Medicare Part D beneficiaries ...
ophthalmologytimes1d
Study explores the true costs of treating pediatric cataracts
Pediatric cataract surgeries are more costly than adult procedures, with significant nonsurgical expenses like anesthesia and ...
ophthalmologytimes1d
Noninvasive choroidal vessel analysis using deep learning: A novel approach to OCT angiography
Peking University researchers have developed a deep learning-based, noninvasive choroidal angiography method that enables ...
ophthalmologytimes4d
Researchers offer insights into wet AMD: Study reveals potential to enhance anti-VEGF therapy with experimental drug to preserve vision
A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...
ophthalmologytimes6d
FDA grants fast track status to FELIQS’ FLQ-101 for ROP
FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.
ophthalmologytimes6d
LumiThera’s Valeda Light Delivery System receives marketing authorization from FDA
The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).
ophthalmologytimes6d
Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007
Formosa Pharmaceuticals has announced the completion and top-line results from CPN-303, a phase 3 clinical study of APP13007 ...
ophthalmologytimes6d
Study: Aromatherapy decreased postoperative patient anxiety and pain associated with oculoplastic surgery
The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for ...
ophthalmologytimes5d
Adapting glaucoma training and treatment: Insights from the Orbis Flying Eye Hospital
Omar Salamanca, MD, staff ophthalmologist, Orbis Flying Eye Hospital, discusses Orbis's tailored glaucoma training programs, which focus on hands-on surgical skills, early detection, telemedicine, and ...
ophthalmologytimes6d
Phase 3 LUGANO Trial explores EYP-1901’s potential to reduce treatment burden in wet AMD Patients
In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...